Which peptides act through incretin mimetic?
-
16Lr
Liraglutide
Earlier-generation GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; licence status depends on the brand.
Metabolic and incretinHuman trialsEvidence reviewedModerateLicensed UK medicine -
17Mz
Mazdutide
Not authorised in the UK; approved in China. Peptide that activates glucagon and GLP-1 receptors, studied in phase 3 trials in Chinese adults.
Metabolic and incretinHuman trialsEvidence reviewedStrongNot licensed in the UK -
22Rt
RetatrutideLY3437943
Investigational triple GIP, GLP-1 and glucagon receptor agonist studied for weight management. Not licensed in the UK; studied in a Phase 2 trial.
Metabolic and incretinHuman trialsEvidence reviewedModerateNot licensed in the UK -
24Sm
Semaglutide
GLP-1 receptor agonist studied in type 2 diabetes, weight management and cardiovascular outcomes. UK prescription-only medicine; studied in large randomised trials.
Metabolic and incretinHuman trialsEvidence reviewedStrongLicensed UK medicine -
28Sv
Survodutide
Investigational peptide that activates glucagon and GLP-1 receptors. Not authorised in the UK. Studied in phase 3 trials, all sponsor-funded.
Metabolic and incretinHuman trialsEvidence reviewedStrongNot licensed in the UK -
34Tz
Tirzepatide
Dual GIP and GLP-1 receptor agonist studied in type 2 diabetes and weight management. UK prescription-only medicine; studied in large randomised trials.
Metabolic and incretinHuman trialsEvidence reviewedStrongLicensed UK medicine
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.